Acro Biomedical (ACBM) Net Income towards Common Stockholders (2016 - 2026)
Acro Biomedical (ACBM) posted Net Income towards Common Stockholders of -$17554.0 for Q2 2026, down 127.53% on a QoQ basis from $63767.0 in Q4 2025, and down 12.8% year-over-year from -$20130.8 in Q2 2025.
Powered by 
Analysis
Acro Biomedical (ACBM) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends
Acro Biomedical has reported Net Income towards Common Stockholders for 11 years, with the latest figure at -$17554.0 in Q2 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 12.8% year-over-year to -$17554.0 in Q2 2026; TTM through Jun 2026 was -$87158.0, a 130.07% decrease from a year earlier, with the FY2025 full-year figure at -$79905.0, down 139.13% from the prior year.
- Net Income towards Common Stockholders was -$17554.0 for Q2 2026 at Acro Biomedical, down from $63767.0 in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $1.8 million in Q4 2023, with the low at -$4.0 million in Q3 2022.
- Average Net Income towards Common Stockholders over 5 years is -$1.4 million, with a median of -$17554.0 recorded in 2026.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders slumped 6503.69% in 2022, then soared 3660.41% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$3.9 million in 2022, then soared by 146.54% to $1.8 million in 2023, then tumbled by 100.1% to -$1791.0 in 2024, then jumped by 3660.41% to $63767.0 in 2025, then tumbled by 127.53% to -$17554.0 in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$17554.0 (Q2 2026), $63767.0 (Q4 2025), and -$117809.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Colgate Palmolive | 70.27 Bn | 68.90 Bn | 3.30 Bn | 719.00 Mn |
| 2 | Kenvue | 34.17 Bn | 33.06 Bn | 2.30 Bn | 456.00 Mn |
| 3 | Kimberly Clark | 32.86 Bn | 31.91 Bn | 1.60 Bn | 295.00 Mn |
| 4 | Bath & Body Works | 3.85 Bn | 3.05 Bn | 692.00 Mn | 118.00 Mn |
| 5 | Prestige Consumer Healthcare | 2.32 Bn | 2.26 Bn | - | - |
| 6 | Perrigo | 1.99 Bn | 1.59 Bn | 313.90 Mn | 74.40 Mn |
| 7 | Herbalife | 1.32 Bn | 946.20 Mn | 1.03 Bn | -26.50 Mn |
| 8 | Edgewell Personal Care | 1.24 Bn | 842.99 Mn | 242.50 Mn | 13.70 Mn |
| 9 | TFA Therapeutics | 1.02 Bn | 1.02 Bn | - | - |
| 10 | Acro Biomedical | 1.80 Mn | 1.80 Mn | - | -17,554.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17,554.00 |
| Dec 31, 2025 | 63,767.00 |
| Sep 30, 2025 | -117,809.00 |
| Jun 30, 2025 | -15,562.00 |
| Mar 31, 2025 | -10,301.00 |
| Dec 31, 2024 | -1,791.00 |
| Sep 30, 2024 | -10,229.00 |
| Jun 30, 2024 | -10,143.00 |
| Mar 31, 2024 | -11,252.00 |
| Dec 31, 2023 | 1.83 Mn |
| Sep 30, 2023 | -1.59 Mn |
| Jun 30, 2023 | -3.20 Mn |
| Mar 31, 2023 | -4.00 Mn |
| Dec 31, 2022 | -3.93 Mn |
| Sep 30, 2022 | -4.01 Mn |
| Jun 30, 2022 | -4.00 Mn |
| Mar 31, 2022 | -3.93 Mn |
| Dec 31, 2021 | -2.24 Mn |
| Sep 30, 2021 | -2.99 Mn |
| Jun 30, 2021 | -794,687.00 |